Syndecans in heart fibrosis

Area of Science:

• Cardiovascular Biology
• Extracellular Matrix Biology
• Proteoglycan Research

Background:

• Heart disease affects millions globally, with cardiac fibrosis central to its pathology.
• The mechanisms underlying heart disease and fibrosis are not fully understood, representing an unmet clinical need.
• Syndecans (syndecan-1 to -4), a family of transmembrane proteoglycans, are implicated in regulating fibrosis.

Purpose of the Study:

• To review the current literature on the role of syndecans in cardiac fibrosis.
• To explore the mechanisms by which syndecans influence extracellular matrix remodeling in the heart.
• To discuss the potential of syndecans and their shedding as therapeutic targets and prognostic tools for heart disease.

Main Methods:

• Review of existing scientific literature on syndecans and cardiac fibrosis.
• Analysis of studies involving syndecan-deficient mice (syndecan-1 and -4) in models of cardiac injury.
• Examination of the molecular structure and function of syndecan ectodomains and their interaction with extracellular matrix components.

Main Results:

• Syndecan expression is upregulated in response to pro-inflammatory stimuli in fibrotic heart disease.
• Mice lacking syndecan-1 and -4 exhibit reduced pro-fibrotic signaling and increased cardiac rupture post-infarction.
• Shed syndecan ectodomains in blood correlate with hospitalization, mortality, and cardiac remodeling in heart failure patients.

Conclusions:

• Syndecans play a critical role in regulating cardiac fibrosis through both signaling and extracellular matrix interactions.
• Syndecan shedding releases ectodomains that influence extracellular matrix remodeling and can serve as prognostic markers.
• Further understanding of syndecans and their modifying enzymes offers potential for developing novel therapeutic strategies for fibrotic heart disease.